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Summary The expression of transferrin receptor (TfR) has been identified in many malignant tumours. In lung cancer, lymphoma and breast
cancer, it has been shown that the expression of TfR correlates with tumour differentiation, probably implying some prognostic value.
A soluble form of TfR (sTfR) in human serum has been shown to be proportional to the number of cellular TfRs. Based on these data we
examined the utility of measuring sTfR in the serum and bronchoalveolar lavage (BAL) fluid of patients with lung cancer (n = 32) and patients
with chronic obstructive pulmonary disease (n = 22). BAL fluid was centrifuged to separate the supernatant from the cellular component. Cells
were lysed in a detergent and cell-associated TfR was measured by enzyme-linked immunosorbent assay (ELISA) and expressed as ng 106
cells in this cellular component. There was no difference in serum sTfR between the cancer and chronic obstructive pulmonary disease
(COPD) groups. A higher level of cell-associated TfR was found in BAL of non-small-cell lung cancer patients than in COPD patients (P =
0.01). The calculated number of TfR molecules per cell in BAL correlated positively with the percentage of macrophages in BAL (P< 0.0001),
suggesting that cell-associated TfR in BAL originates primarily from macrophages in this fluid. No correlation existed between BAL cell-
associated TfR and tumour size, nodal status, the presence of metastases and serum sTfR. BAL cell-associated TfR was negatively
correlated with BAL supernatant neuron-specific enolase (NSE) (P = 0.01). A combination of BAL supernatant NSE and cell-associated TfR
detected lung cancer with a sensitivity of 91%, a specificity of 59% and positive and negative predictive values of 81% and 71% respectively.
In conclusion, BAL cell-associated TfR may help in the differential diagnosis of lung cancer vs pneumonia.
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Iron transport in the plasma is carried out by transferrin, which
donates iron to cells through its interaction with a specific membrane
receptor, the transferrin receptor (TfR). Immunohistochemical
staining for TfR has been used most extensively for measuring the
proliferation rate of cells and is thought to be of some prognostic
value in several types of malignant tumours (Faulk et al, 1980;
Habelshaw et al, 1983; Wrba et al, 1986). It has also been demon-
strated that TfR expression, detected by the monoclonal antibody
OKT9, is correlated in pulmonary adenocarcinoma with the degree
of histological differentiation, the degree of nuclear atypia and
mitotic index and is thus important in prognosis of these malignant
tumours (Kondo etal, 1990). A solubleform ofTfR(sTfR) inhuman
serum has been shown to be proportional to the number of cellular
TfRs (Chitambar et al, 1989). Furthermore, it has recently been
demonstrated that bronchoalveolar lavage (BAL) fluid is a suitable
place to measure certain markers for lung cancer (De Diego et al,
1991; Dowlati et al, 1996).
Based on these preliminary data we investigated the utility of
measuring sTfR in the serum and bronchoalveolar lavage fluid of
patients with lung cancer. To appreciate the diagnostic value of
TfR measurements we compared them with values obtained in a
group of chronic obstructive pulmonary disease (COPD) patients
with similar smoking habits.
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MATERIALS AND METHODS
Patients
A total of 54 patients were enrolled in this study. The first group
consisted of 32 patients with lung cancer, of which 23 had non-
small-cell lung cancer (NSCLC) and nine had small-cell lung
cancer (SCLC). All patients were newly diagnosed and none had
received any kind of treatment for their cancer nor had received
blood transfusions. Diagnosis of lung cancer was performed in 28
of these patients by bronchial biopsy or transbronchial forceps
biopsy and in four by thoracotomy. Mean age was 66 (range
49-76) with a male to female ratio of9:1. Thirty ofthe 32 patients
in this group were heavy smokers. The mean smoking pack-year
value among smokers was 25. The second group were patients (n =
22) with chronic obstructive pulmonary disease (COPD), all of
whom were heavy smokers with mean smoking pack-year value
of 24. Fibreoptic bronchoscopy was performed in these patients
for an episode of either infectious bronchitis or pneumonia. The
diagnosis of infectious bronchitis and pneumonia was made by
response to antibiotic therapy, the detection of causative bacteria
on bronchial aspiration and no evidence of cancer at the 1.6-year
follow-up. The mean age in this group was 62 (range 41-77) with
a male to female ratio of 6:1. No difference existed in the age of
the two groups or in the pack-year smoking value.
*Present address: Division ofHaematology/Oncology, CaseWestern Reserve
University, Cleveland, OH, USA.
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Fibreoptic bronchoscopy, BAL and serum collection
BAL was performed according to the European BAL Task Group
norms (Klech and Hutter, 1990). The tip ofthe fibreoptic broncho-
scope was wedged into the affected bronchus or to the one closest
to the lesion in the tumour group and into the lingula or middle
lobe in the group with COPD. Subsequently, 150 ml of 0.9%
sterile saline serum was instilled in three aliquots of 50 ml. The
fluid ofeach instillation was recovered by gentle suction. The total
aspirated volume was transferred to the laboratory where the fluid
was centrifuged at 500gfor 10 min to separate the cellularcompo-
nent from the supernatant. The number of cells per ml of the
cellular component was then determined. Differential cell counts
were performed on this cellular component. The cellular compo-
nent of BAL fluid was homogenized with 1 ml of a detergent
solution [phosphate-buffered saline (PBS), 2% polyoxyethylene
9 lauryl ether and protease inhibitors] for 30 s at 15 000 r.p.m. and
15 s at 24 000 r.p.m. in order to rupture the cellular membrane and
release cell-associated TfR into the solution. This solution was
then centrifuged at 20 000 r.p.m. for 20 min at 4°C to eliminate
cell ghosts. The solubilized cell-associated TfR in this solution
was measured by the enzyme linked immunosorbent assay
(ELISA) method described below and expressed as ng 10- cells.
The sTfR was also measured in the supernatant and expressed as
ng per ml. Blood was drawn the same day as the BAL and serum
sTfR was measured in the serum according to the ELISA method.
Soluble TfR assay
An ELISA (Huebers et al, 1990) with minor modifications was
used to measure serum and BAL fluid sTfR levels. Each sample
was run in triplicate. The between-assay variability (coefficient of
variation) was 7.2% when the same control sample was measured
in each plate. Serum sTfR levels were available in 26 patients in
the cancer group and 16 patients in the COPD group.
Staging
Tumour staging for NSCLC was carried out using conventional
imaging techniques [chest and abdominal computerized tomog-
raphy (CT) scans, total body bone scintigraphy and cerebral CT
scans ifclinically relevant]. Assignment to T, N and M was made
using the Union Internationale contre le Cancer (UICC) TNM
staging system. The results of TNM staging were then classified
into overall stages of I-IV according to the American Joint
Committee on Cancer staging criteria (American Joint Committee
on Cancer. Lung, 1992). The nine cases ofSCLC were categorized
as being either localized or extensive disease (Stahel et al, 1989).
The results ofclinical staging in NSCLC were as follows: TI = 3,
T2=4,T3= 10,T4=6,NO=7,N1 =4,N2=5,N3=7,Ml =5,
stage I = 1, stage II = 1, stage III = 16, stage IV = 5. In SCLC there
were four cases oflimited and five cases ofextensive disease.
Neuron-specific enolase (NSE) measurements
NSE measurements on the supernatant of BAL fluid were
performed using a commercial kit (Cis Bio-International, Gif-sur-
Yvette, France) according to the manufacturer's instructions.
Lactate dehydrogenase (LDH) levels were determined by the
photometric method using a commercial kit (Merck, Darmstadt,
Germany). Results of NSE in BAL fluid were expressed as
nanograms (ng) per 100 interuational units (IU) of LDH. The
values of BAL fluid NSE expressed as ng 100-1 IU LDH were
calculated as individual ratio values; that is the absolute value of
NSE in BAL was multiplied by 100 and then divided by the
absolute value ofLDH in the BAL ofeach subject. This was done
in order to compensate the diluting effect ofBAL.
Statistics
All data are expressed as means ± standard deviation. Values of
serum sTfR were transformed to their corresponding logarithmic
values in orderto achieve normality in distribution. Student's t-test
was used to assess the significance of differences between the
groups. A probability of 0.05 was considered significant. Linear
regression and Spearman's correlation coefficient were used to
assess association between some of the parameters. ANOVA was
used to detectdifferences in sTfR measurements between different
T, N and M groups. Sensitivity, specificity andpredictive values of
sTfR and NSE measurements were determined using 2 x 2 contin-
gency tables. The log-rank test was used to compare survival rates
between the appropriate groups.
RESULTS
Levels of TfR solubilized from the cellular component of BAL
fluid (expressed as ng 10-6 cells) are shown in Figure 1. There was
a significant difference in BAL fluid cell-associated TfR levels
between NSCLC (612 ± 337) and COPD (353 ± 337, P = 0.01).
There was also a significant difference between NSCLC and
SCLC (330 ± 369, P = 0.04). There was no difference between
SCLC and COPD (P= 0.9). The median percentage of macro-
phages in the cellular component ofBAL fluid forNSCLC was 75
(range 25-96) for SCLC 54 (range 4-97) and for COPD 72 (range
2-100). The difference in the percentage ofmacrophages between
the three groups was statistically non-significant (P = 0.18). In
order to elucidate the origin of TfR solubilized from the cellular
component of BAL fluid, correlation was sought between the
percentage of macrophages in BAL and the calculated number
of molecules of TfR per cell in this fluid. In the cancer group a
highly significant correlation existed between the percentage of
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Figure 1 Levels of cell-associated TfR in BAL fluid expressed as ng 10-6
cells. A significantly higher level is found in NSCLC than in COPD (P= 0.01)
and in SCLC (P= 0.04)
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Figure 2 Correlation between the number of calculated molecules of TfR per
cell in the cellular component of BAL and the percentage of macrophages in
this fluid. This correlation is highly significant (r = 0.73, P < 0.0001)
macrophages and the number of molecules of TfR per cell in the
BAL cellular component (r = 0.73, P < 0.001, Figure 2). Indeed
very little cell-associated TfR was detected when the percentage of
macrophages was below 50%; accordingly, when samples with less
than 50% were excluded from the analysis the correlation between
the number of molecules of TfR per cell and the percentage of
macrophages became non-significant (r = 0.29, P = 0.17),
suggesting that a critical number of macrophages must be present
in the cellular component of BAL fluid in order to have a signifi-
cant level ofcell-associated TfR. This correlation was also signifi-
cant forthe COPD group (r = 0.49, P = 0.02). When cell-associated
TfR in BAL fluid was expressed as ng 106 macrophages the differ-
ence between NSCLC (881 ± 357) and COPD (564 ± 414)
remained significant (P = 0.01); however, the difference between
NSCLC and SCLC (655 356) became non-significant (P = 0.10).
No correlation was found between the absolute numbers of
macrophages in BAL per ml (222 640 ± 436 000) and BAL cell-
associated TfR (P = 0.7). No correlation existed between BAL cell-
associated TfR and tumour size (P = 0.3), nodal status (P = 0.7)
and the presence of metastases (P = 0.2).
BAL supernatant sTfR was also measured. Because the limit of
detection of the current ELISA method for sTfR is 2 ng ml-1, 8 of
30 cancer patients (levels were available in 30 of 32 cancer
patients) had non-dosable levels of sTfR in the BAL supernatant
and 22 had values 2 10 ng ml (30.3 ± 45.6). The correlation
between sTfR in the supernatant of BAL and cell-associated TfR
in BAL did not reach statistical significance (P = 0.07).
The serum levels of sTfR (jg 1-') were as follows: NSCLC
(2932 ± 1950), SCLC (2695 ± 687) and COPD (3213 ± 855).
Based on previous studies the value of serum sTfR in normal indi-
viduals is 5000 ± 1100 ng ml-1 (Beguin et al, 1992a). No difference
could be found between the three groups in our study (P = 0.9).
Furthermore, there was no relation between serum sTfR and BAL
supernatant or cell-associated TfR. In the cancerpatients, no corre-
lation was found between serum sTfR on the one hand and serum
ferritin (255 ± 155 jg 1-1, P = 0.2), TIBC (41.3 ± 9.5 ,umol 1-1, P =
0.5) or serum iron (12.1 ± 7.8 gmol 1-1, P = 0.1) levels on the other.
Only five patients had serum ferritin below 100 jg 1-1, the lowest
value being 50 jg ml-'. Based on serum ferritin levels, patients
with cancer were divided into two groups: 200 or < 200 pmol 1-1.
2000
1500
1000
o 1
, 1o
a
NSE in BAL supernatant (ng 100 IU-1 LDH)
Figure 3 Correlation between the cell-associated TfR levels in BAL and NSE
levels in the supernatant of BAL. The correlation is negative and statistically
significant (r = -0.423, P = 0.01)
No difference was found in the serum sTfR between these two
groups (P = 0.5).
Results of NSE in the supernatant of BAL fluid of the corre-
sponding patients can be found in a previous article (Dowlati et al,
1996). Comparing the results of cell-associated TfR in BAL and
NSE in BAL supernatant (expressed as ng per 100 IU ofLDH), we
found a significant negative correlation between the two parame-
ters (r = -0.423, P = 0.01, Figure 3). Using 500 ng 106 cells as the
cut-offpoint, the sensitivity and specificity ofBAL cell-associated
TfR for detecting NSCLC were 65% and 77% respectively. The
positive and negative predictive values were 75% and 68% respec-
tively. Using a combination of cell-associated TfR in BAL (at the
cut-offpoint mentioned above) and a cut-offpoint for BAL super-
natant NSE of6.6 ng per 100 IU ofLDH, the sensitivity and speci-
ficity forthe diagnosis ofNSCLC were 91% and 59% respectively.
Negative and positive predictive values were 81% and 71%
respectively. Interestingly, BAL fluid NSE had a negative correla-
tion with the percentage of BAL fluid macrophages (r = -0.3551,
P = 0.03).
Using a cut-off point of 750 ng 106 cells ofcell-associated TfR
in BAL, patients with stage III and IV lung cancer were divided
into two groups. No survival difference was seen between these
two groups (log-rank test, P = 0.57, Figure 4).
DISCUSSION
Transferrin functions to maintain cellular proliferation by
providing iron for processes that have yet to be defined. It has been
demonstrated that transferrin synthesis by SCLC acts as an
autocrine regulator of cellular proliferation (Vostrejs et al, 1988).
Immunohistochemical staining for transferrin receptor, which is
needed for internalization of transferrin and iron, has been used
most extensively for measuring the proliferation rate ofcells and is
thought to be of some prognostic value in several types of malig-
nant tumours. All cells except mature red blood cells express the
transferrin receptor. Since Faulk et al (1980) reported that TfR was
observed in breast cancer, the expression of TfR has been identi-
fied in many types of malignant tumours including malignant
lymphoma (Habelshaw et al, 1983), gastric cancer (Gatter et al,
1983), uterine cancer (Lloyd et al, 1981) and lung cancer
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Figure 4 Comparison of survival in patients with stage III or IV NSCLC with
cell-associated TfR levels in BAL .750 ng 10- cells or <750 ng 10- cells. No
survival difference is seen (log-rank test, P= 0.57)
(Sato et al, 1985). In malignant lymphoma (Habelshaw et al, 1983)
and breast cancer (Faulk et al, 1980; Wrba et al, 1986), it has been
shown that the expression ofTfR correlates with tumour differen-
tiation, probably implying some prognostic significance. It has
also been demonstrated that TfR expression, detected by the
monoclonal antibody OKT9, is correlated in pulmonary adeno-
carcinoma with the degree of histological differentiation, the
degree ofnuclear atypia and mitotic index, and may thus be impor-
tant in prognosis ofthe malignant tumours (Kondo et al, 1990). A
soluble form ofTfR has also been detected in the serum. An excel-
lent correlation between cellular TfR and soluble TfR (sTfR) has
been demonstrated both in vivo and by incubations of tumour cell
lines (Chitamber et al, 1989). Based on these data, we measured
serum sTfR levels as well as supematant sTfR and cell-associated
TfR in BAL fluid ofpatients with lung cancer and compared them
with values obtained in a group ofCOPD patients. COPD patients
were used as the control group because they have similar smoking
habits to lung cancer patients.
Our study shows that cell-associated TfR levels are significantly
higher in the BAL fluid of NSCLC patients than in SCLC and
COPD patients. The study by Kondo et al (1990) also showed high
expression of cellular TfR in adenocarcinoma of the lung.
However, our study indicates that cell-associated TfR in BAL
fluid probably originates mainly from macrophages found in this
fluid and not directly from tumour cells. We have also demon-
strated that cell-associated TfR levels in BAL fluid are negatively
correlated with BAL NSE levels and that BAL NSE levels are
inversely related to the percentage of macrophages in this fluid.
Furthermore, our previous study suggests that BAL fluid levels of
NSE are a reflection oftheir local tumour cell expression, which is
not the case for cell-associated TfR (Dowlati et al, 1996). The
correlation between BAL supematant sTfR and cell-associated
TfR levels did not reach statistical significance, probably because
values in supernatant were very low and thus less precise.
BAL fluid analysis for markers oflung cancer has recently been
shown to be interesting. De Diego et al (1991) showed that the
combined measurements of serum CEA and BAL fluid CEA has
sensitivity and specificity of 88% for lung cancer with a positive
predictive value of 66% when compared with patients with pneu-
monia. We have previously shown that NSE in BAL fluid is a
better predictor ofmalignancy than serum NSE and that no relation
exists between serum and BAL levels ofthis marker (Dowlati et al,
1996). The findings in this study further confirm that levels of
markers such as TfR and NSE (Dowlati et al, 1996) in BAL fluid
have no relation to their corresponding serum levels. In addition,
cell-associated TfR proved to have predictive value for the diag-
nosis of cancer and that the sensitivity of this prediction could be
improved by combining it with BAL supematant NSE levels. The
combination of multiple markers in BAL may thus contribute to
the diagnosis ofperipheral lung cancers for which obtaining histo-
logical diagnosis is difficult.
Although tissue expression of TfR has been shown to be corre-
lated with the degree of histological differentiation, the degree of
nuclearatypia and mitotic index, ithas notbeen shown thatthis is an
independent prognostic factor. Accordingly, our study has failed to
show a survival difference between patients with high cell-associ-
ated TfR in the cellular component of BAL fluid and patients with
lower levels. This might be due to the limited number ofpatients in
our study and we believe that a study with a larger number of
patients should be conducted to clarify the prognostic significance
ofcell-associated TfR in BAL fluid ofNSCLC patients.
In our study serum sTfR levels were 'low'. In a group of 165
normal human subjects, receptor levels in the serum averaged
5000 ± 1100 ng ml-' (Beguin, 1992). In the serum sTfR levels are
essentially a reflection of erythropoiesis (Huebers et al, 1990).
Consequently, in the presence of anaemia of chronic disease,
patients with solid tumours and multiple myeloma may have
normal or low levels ofserum sTfR (Beguin et al, 1992; Raafet al,
1993). However, levels of serum sTfR are increased in chronic
lymphocytic leukaemia (Beguin et al, 1993) and erythroid malig-
nancies (Huebers et al, 1990, Klemow et al, 1990), and possibly
hepatocarcinoma (Kohgo et al, 1991). Our study thus shows that
serum sTfR levels are not increased in lung cancer and that they do
not differ from levels in COPD patients. The lower levels ofserum
sTfR in our series of lung cancer patients can be interpreted as a
state of erythroid hypoplasia in the context of anaemia of chronic
disease and can rule out iron deficiency (Ferguson et al, 1992). No
correlation was seen between serum sTfR and ferritin, TIBC or
serum iron. Because serum ferritin levels are frequently elevated
in advanced cancer, using ferritin alone for the diagnosis of iron
deficiency is not reliable. However, as very few patients had serum
ferritin levels < 100 ,ug 1-1 and none had elevated serum sTfR
levels, iron deficiency can be excluded fairly in our patients.
ACKNOWLEDGEMENTS
Martine Loo was supported by research fellowships from
'Televie' (National Fund for Scientific Research) and 'Fondation
Freddrick' (University of Liege). Yves Beguin is a Senior
Research Associate of the National Fund for Scientific Research
(FNRS, Belgium). This work was supported in part by grants no.
3.4555.91 of the FRSM (Fund for Medical Scientific Research)
and no. 3.4621.94 of the FNRS.
REFERENCES
American Joint Committee on Cancer. Lung (1992) Manual for the staging of
cancer, Beahrs OH, Henson DE and Hutter RVP (eds), pp. 115-122. JB
Lippincott: Philadelphia
Beguin Y (1992) The soluble transferrin receptor: hiological aspects and clinical
usefulness as quantitative measure of erythropoiesis. H-aematologica 77: 1-10
C Cancer Research Campaign 1997 British Joural of Cancer (1997) 75(12), 1802-18061806 A Dowlati etal
Beguin Y, Yerna M, Loo M, Weber M and Fillet G (1992) Erythropoiesis in multiple
myeloma: defective red cell production due to inappropriate erythropoietin
production. BrJ Haematol 82: 648-653
Beguin Y, Lampertz S, De Groote D, Igot D, Malaise M and Fillet G (1993) Soluble
CD23 and other receptors (CD4, CD8, CD25, CD71) in serum ofpatients with
chronic lymphocytic leukemia. Leukemia 7: 2019-2025
Chitambar CR and Zivkovic Z (1989) Release of soluble transferrin receptor from
the surface ofhuman leukemic HL60 cells. Blood74: 602-608
De Diego A, Compte L, Sanchis J, Enguidanos MJ and Marco V (1991) Usefulness
ofcarcinoembryonic antigen determination in bronchoalveolar lavage fluid.
Chest 100: 1060-1063
Dowlati A, Bury T, Corhay JL, Weber T, Mendes P and Radermecker M (1996) High
neurone specific enolase levels in bronchoalveolar lavage fluid ofpatients with
lung carcinoma. Cancer 77: 2039-2043
Faulk WP, Hsi BL and Stevens PJ (1980) Transferrin and transferrin receptors in
carcinoma ofthe breast. Lancet 2: 390-392
Ferguson BJ, Skikne BS, Simpson KM, Baynes RD and Cook JD (1992) Serum
transferrin receptor distinguishes the anaemia ofchronic disease from iron
deficiency anaemia. J Lab Clin Med 119: 385-390
Gatter KC, Brown G, Trowbridge IS, Woolston RE and Mason DY (1983)
Transferrin receptors in human tissues: their distribution and possible clinical
relevance. J Clin Pathol 36: 539-545
Habelshaw JA, Lister TA and Stansfeld AG (1983) Correlation oftransferrin
receptor expression with histological class and outcome in non-Hodgkin
lymphoma. Lancet 1: 498-500
Huebers HA, Beguin Y, Pootrakul P, Einspahr D and Finch CA (1990) Intact transferrin
receptors in human plasma and theirrelation to erythropoiesis. Blood75: 102-107
Klech H and Hutter C (1990) Clinical guidelines and indications for bronchoalveolar
lavage (BAL): report ofthe European Society ofPneumology Task Group on
BAL. Eur Respir J 3: 937-974
Klemow D, Einsphar D, Brown TA, Flowers CH and Skikne BS (1990) Serum
transferrin receptor measurements in hematologic malignancies. Am J Hematol
34: 193-198
Kohgo Y, Kondo H, Mogi Y and Niitsu Y (1991) Mechanism and clinical
signific,ance of soluble hepatic cell-surface receptors. Targeted Diagn Ther 4:
305-319
Kondo K, Masayuki N, Mukai K, Matsuno Y, Sato Y, Shimosato Y and Monder Y
(1990) Transferrin receptor expression in adenocarcinoma ofthe lung as a
histopathological indicator of prognosis. Chest 97: 1367-1371
Lloyd JM, O'Dowd T, Driver M and Tee D (1984) Demonstration ofan epitope of
the transferrin receptor in human cervical epithelium - a potentially useful cell
marker. J Clin Pathol 37: 131-135
RaafHN, Jacobsen DW, Savon S and Green R (1993) Serum transferrin receptor
level is not altered in invasive adenocarcinoma ofthe breast. Am J Clin Pathol
99: 232-237
Sato Y, Watanabe, Kodama T, Goto M and Shimosato Y (1985) Stainability of lung
cancer cells with Leu-7 and OKT-9 monoclonal antibodies. Jpn J Clin Oncol
15: 537-544
Stahel RA, Ginsberg R and Havermann K (1989) Staging and prognostic factors in
small cell lung cancer: a consensus report. Lung Cancer 5: 119
Vostrejs M, Moran PL and Seligman P (1988) Transferrin synthesis by small cell
lung cancer cells acts as an autocrine regulator ofcellular proliferation. J Clin
Invest 82: 331-339
Wrba F, Ritzinger E, Reiner A and Holzer JH (1986) Transferrin receptor (TrfR)
expression in breast carcinoma and its possible relationship to prognosis.
Virchows Arch 410: 69-73
British Journal ofCancer (1997) 75(12), 1802-1806 C CancerResearch Campaign 1997